MaltSci 麦伴科研

Appearance

Popular Reports / rheumatology

This report is written by MaltSci based on the latest literature and research findings

What is the role of cytokines in rheumatic diseases? ​

Abstract ​

Cytokines are essential signaling molecules that regulate immune responses and play a critical role in the pathogenesis of rheumatic diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and spondyloarthritis. These diseases are characterized by chronic inflammation and autoimmunity, leading to significant morbidity and impaired quality of life. Dysregulation of cytokine production and signaling pathways contributes to the inflammatory processes underlying these conditions, positioning cytokines as both key to understanding disease mechanisms and as potential therapeutic targets. Recent advancements in cytokine research have elucidated the intricate interplay between pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), and anti-inflammatory cytokines, highlighting their effects on immune cell functions and roles in disease progression. The review systematically explores the definition, classification, and mechanisms of action of cytokines, emphasizing their roles in various rheumatic diseases. It further discusses cytokines as biomarkers, their profiles in different conditions, and the clinical implications of measuring these biomarkers. Current therapeutic strategies targeting cytokines, including biologics and JAK inhibitors, are examined, alongside future directions in cytokine modulation. Understanding the multifaceted roles of cytokines is crucial for unraveling the complexities of rheumatic diseases and developing more effective therapeutic strategies. This review aims to contribute to the growing body of literature that underscores the importance of cytokines in rheumatology and their potential as targets for innovative treatments.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Overview of Cytokines
    • 2.1 Definition and Classification of Cytokines
    • 2.2 Mechanisms of Cytokine Action
  • 3 Cytokines in Rheumatic Diseases
    • 3.1 Role of Pro-inflammatory Cytokines
    • 3.2 Role of Anti-inflammatory Cytokines
  • 4 Cytokines as Biomarkers
    • 4.1 Cytokine Profiles in Different Rheumatic Diseases
    • 4.2 Clinical Implications of Cytokine Measurement
  • 5 Therapeutic Targeting of Cytokines
    • 5.1 Current Cytokine-targeted Therapies
    • 5.2 Future Directions in Cytokine Modulation
  • 6 Conclusion

1 Introduction ​

Cytokines are critical signaling molecules that orchestrate immune responses, playing a pivotal role in the pathogenesis of various rheumatic diseases. These diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and spondyloarthritis, are characterized by chronic inflammation and autoimmunity, leading to significant morbidity and impaired quality of life. The dysregulation of cytokine production and signaling pathways contributes to the inflammatory processes that underlie these conditions, making cytokines not only central to understanding disease mechanisms but also potential therapeutic targets. Recent advancements in cytokine research have illuminated the complex interplay between pro-inflammatory and anti-inflammatory cytokines, revealing their effects on immune cell functions and their roles in disease progression[1][2].

The significance of cytokines in rheumatic diseases cannot be overstated. Their involvement in the initiation and perpetuation of inflammation suggests that they could serve as valuable biomarkers for disease activity and therapeutic targets. For instance, the balance between pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), and anti-inflammatory cytokines is crucial in determining the course of these diseases[3][4]. Understanding these dynamics offers insights into not only the pathophysiology of rheumatic diseases but also the development of targeted therapies aimed at modulating cytokine activity[5].

Current research has highlighted the need for more specific intervention strategies, particularly in light of the limitations of existing antirheumatic therapies[3]. The efficacy of these treatments is often hindered by the complexity of cytokine interactions and their regulatory networks. Thus, elucidating the role of cytokines in the pathogenesis of rheumatic diseases is essential for the advancement of therapeutic options[1].

This review will systematically explore the role of cytokines in rheumatic diseases through several key sections. First, we will provide an overview of cytokines, including their definition, classification, and mechanisms of action. This will be followed by an in-depth discussion of the roles of pro-inflammatory and anti-inflammatory cytokines in various rheumatic diseases. We will then examine cytokines as biomarkers, detailing their profiles in different conditions and the clinical implications of measuring these biomarkers. The therapeutic targeting of cytokines will be explored next, highlighting current cytokine-targeted therapies and potential future directions in cytokine modulation. Finally, we will conclude with a synthesis of the findings and a discussion of the importance of continued research in this field to improve patient outcomes.

In summary, understanding the multifaceted roles of cytokines in rheumatic diseases is crucial for unraveling the complexities of these conditions and developing more effective therapeutic strategies. By synthesizing current knowledge, this review aims to contribute to the growing body of literature that underscores the importance of cytokines in rheumatology and their potential as targets for innovative treatments.

2 Overview of Cytokines ​

2.1 Definition and Classification of Cytokines ​

Cytokines are pleiotropic polypeptides that play a crucial role in regulating immune responses, inflammation, and tissue repair. They are classified based on their target receptors, structural features of their extracellular domains, and receptor composition. Functionally, cytokines can be categorized into pro-inflammatory and anti-inflammatory cytokines, hematopoietic colony-stimulating factors, and those involved in developmental processes and wound healing, all of which contribute to maintaining immune homeostasis. An imbalance in cytokine production and interaction can lead to immunopathogenesis, where the immune response becomes dysregulated, potentially resulting in various diseases, including rheumatic diseases such as rheumatoid arthritis (RA) [6].

In the context of rheumatic diseases, cytokines are central mediators of inflammation and play significant roles in the pathophysiology of conditions like RA. They are involved in the processes of inflammation, immune response, and tissue remodeling. In RA, for instance, the ingress of inflammatory leukocytes into the synovium is a critical step in disease pathogenesis, and cytokines mediate these inflammatory events, influencing adhesive mechanisms, angiogenesis, and osteopenia associated with the disease [3]. The imbalance between pro-inflammatory and anti-inflammatory cytokines in the joints of RA patients favors the induction of autoimmunity and chronic inflammation, ultimately leading to joint damage [1].

Specific cytokines have been identified as major players in RA. Tumor necrosis factor-alpha (TNF-α) is one of the most significant cytokines regulating the production of interleukin-1 (IL-1) in the rheumatoid joint, which is pivotal for the inflammatory process in RA but not in osteoarthritis [7]. Other cytokines, such as IL-6 and IL-1, have also been implicated in promoting inflammation and joint destruction, underscoring the therapeutic potential of targeting these cytokines in RA treatment [8].

The therapeutic strategies targeting cytokines have evolved significantly, with the development of biologics that specifically inhibit the effects of these inflammatory mediators. For example, JAK inhibitors have emerged as a promising class of drugs for treating autoimmune and inflammatory diseases, including RA, by inhibiting the JAK-STAT signaling pathway that mediates the effects of several cytokines [9]. This therapeutic approach aims to restore the balance of cytokine activity and mitigate the inflammatory processes characteristic of rheumatic diseases.

In summary, cytokines are pivotal in the pathogenesis of rheumatic diseases, acting as key regulators of inflammation and immune responses. Their classification into various functional categories highlights their diverse roles in health and disease, and ongoing research into cytokine biology continues to inform the development of targeted therapies for conditions like rheumatoid arthritis.

2.2 Mechanisms of Cytokine Action ​

Cytokines are pivotal mediators in the pathogenesis of rheumatic diseases, particularly rheumatoid arthritis (RA), where they orchestrate various inflammatory processes. The complex interplay of cytokines in RA is crucial for understanding the disease's progression and potential therapeutic interventions.

Cytokines can be broadly categorized into pro-inflammatory and anti-inflammatory types. In RA, an imbalance favoring pro-inflammatory cytokines leads to the induction of autoimmunity and chronic inflammation, ultimately resulting in joint destruction. Key pro-inflammatory cytokines include tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6). TNF-α, in particular, has been identified as a major signal regulating the production of other cytokines, including IL-1, thereby amplifying inflammatory responses in the synovial tissue of RA patients [10].

The mechanisms by which cytokines exert their effects involve binding to specific high-affinity receptors on target cells, initiating intracellular signaling cascades that lead to various biological responses. For instance, TNF-α and IL-6 play significant roles in promoting synovial cell proliferation and inflammatory cell recruitment, which are critical for the development of synovitis, a hallmark of RA [11].

Cytokines also contribute to the recruitment and activation of leukocytes, including neutrophils and monocytes, into the inflamed synovium. Chemokines, a subset of cytokines, are specifically responsible for directing the migration of these immune cells to sites of inflammation [12]. The ongoing production of cytokines in the rheumatoid joint reflects the persistent inflammatory environment, which is a characteristic of autoimmune diseases [3].

Recent advancements in understanding cytokine networks have revealed the involvement of additional cytokines, such as IL-7, IL-17, IL-21, IL-23, and granulocyte-macrophage colony-stimulating factor (GM-CSF), which further complicate the cytokine landscape in RA [13]. This complexity highlights the potential for therapeutic stratification based on specific cytokine profiles, which could lead to more targeted and effective treatments in the future [11].

In summary, cytokines are central to the pathogenesis of rheumatic diseases through their roles in mediating inflammation, regulating immune responses, and contributing to joint damage. The hierarchical organization of cytokine interactions presents both challenges and opportunities for therapeutic intervention, as blocking specific cytokine pathways has shown considerable success in clinical settings [1]. The continued exploration of cytokine dynamics and their signaling mechanisms will be crucial for developing innovative treatment strategies for rheumatic diseases.

3 Cytokines in Rheumatic Diseases ​

3.1 Role of Pro-inflammatory Cytokines ​

Cytokines play a pivotal role in the pathogenesis of rheumatic diseases, particularly rheumatoid arthritis (RA). These protein mediators are involved in various inflammatory processes, immune responses, and tissue remodeling. The intricate network of cytokines orchestrates both innate and adaptive immune responses, which are critical in the development and progression of these diseases.

In RA, the imbalance between pro-inflammatory and anti-inflammatory cytokines significantly contributes to the induction of autoimmunity and chronic inflammation. Key pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), are central to the inflammatory processes observed in RA. These cytokines promote synovial cell proliferation and mediate the damage to cartilage and bone, leading to joint destruction and disability[13].

Recent research has expanded the understanding of the cytokine landscape in RA, revealing the involvement of additional cytokines such as IL-1β, IL-17, IL-21, IL-23, granulocyte macrophage colony-stimulating factor (GM-CSF), IL-18, IL-33, and IL-2[11]. This broad array of cytokines underscores the complexity of the inflammatory milieu in RA, where multiple cytokines can interact and amplify inflammatory signals, further exacerbating the disease process[8].

The success of biologic therapies targeting these cytokines, particularly anti-TNF therapies, has highlighted their crucial role in disease management. These therapies have not only provided remarkable therapeutic advances but also helped delineate the hierarchical roles of specific cytokines in RA pathogenesis[14]. The identification of cytokines that play significant roles in the disease process has led to the development of therapeutic strategies aimed at cytokine inhibition, which includes monoclonal antibodies and soluble cytokine receptors[3].

Moreover, cytokines are involved in the regulation of angiogenesis and the recruitment of inflammatory leukocytes to the synovium, which are essential processes in the pathogenesis of RA[12]. The chemokines, a subset of cytokines, mediate the ingress of leukocytes into inflamed tissues, thereby facilitating the inflammatory response and contributing to the chronic nature of rheumatic diseases[11].

In summary, pro-inflammatory cytokines are central to the pathogenesis of rheumatic diseases, particularly RA. They mediate key processes such as inflammation, joint destruction, and immune dysregulation. Understanding the roles of these cytokines not only enhances the comprehension of disease mechanisms but also opens avenues for targeted therapeutic interventions that can significantly improve patient outcomes.

3.2 Role of Anti-inflammatory Cytokines ​

Cytokines play a crucial role in the pathogenesis of rheumatic diseases, particularly rheumatoid arthritis (RA). They are protein mediators that facilitate various processes including inflammation, immune response, cell growth, repair, and fibrosis. In active autoimmune diseases such as RA, cytokines are continuously produced, contributing to the chronic inflammation and joint damage characteristic of the disease [10].

In RA, there is a complex interplay of pro-inflammatory and anti-inflammatory cytokines. Key pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), have been identified as central to the disease's pathogenesis. These cytokines promote synovial cell proliferation and lead to damage in cartilage and bone [13]. The balance between pro-inflammatory and anti-inflammatory cytokines is critical; an imbalance can exacerbate the disease process, leading to increased inflammation and joint destruction [8].

Anti-inflammatory cytokines, on the other hand, serve to counteract the effects of pro-inflammatory cytokines. They help to regulate the immune response and can potentially mitigate tissue damage. For instance, cytokines like interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β) are involved in suppressing inflammation and promoting healing [11]. The therapeutic targeting of these cytokines has shown promise in clinical settings, leading to significant advances in treatment strategies for RA.

The success of biologic therapies that inhibit pro-inflammatory cytokines underscores the importance of cytokine networks in rheumatic diseases. For example, anti-TNF therapies have revolutionized the management of RA, demonstrating that effectively blocking specific cytokines can lead to improved clinical outcomes [14]. This highlights the potential for further therapeutic stratification based on the specific cytokine profiles present in individual patients, thereby allowing for more personalized treatment approaches [11].

In summary, cytokines are pivotal in shaping the immunological landscape of rheumatic diseases, influencing both disease progression and the response to treatment. Understanding the roles of both pro-inflammatory and anti-inflammatory cytokines can provide insights into more effective therapeutic strategies for managing these complex conditions.

4 Cytokines as Biomarkers ​

4.1 Cytokine Profiles in Different Rheumatic Diseases ​

Cytokines play a pivotal role in the pathophysiology of rheumatic diseases, particularly in conditions such as rheumatoid arthritis (RA), systemic lupus erythematosus, and other autoimmune and inflammatory disorders. They are key mediators in the inflammatory processes that characterize these diseases, influencing both the onset and progression of autoimmune responses.

In the context of rheumatoid arthritis, cytokines are involved in several critical processes, including the ingress of inflammatory leukocytes into the synovium, which is a crucial step in the disease's pathogenesis. Pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), contribute to the inflammatory milieu, promoting joint damage and chronic inflammation. Conversely, anti-inflammatory cytokines play a role in regulating these processes, although an imbalance between pro- and anti-inflammatory cytokines often leads to disease exacerbation and tissue damage [1][3].

Cytokines are not only important in the disease mechanism but also serve as valuable biomarkers for diagnosis and monitoring disease activity in patients with rheumatic diseases. The assessment of cytokine levels can provide insights into the immunological state of a patient and help to evaluate therapy responses. For instance, serum and intracytoplasmic cytokines have been shown to reflect the severity of autoimmune diseases and can guide treatment decisions [15].

In various rheumatic conditions, distinct cytokine profiles can be observed. For example, elevated levels of specific cytokines may indicate active disease states, while others may correlate with disease remission. This highlights the potential of using cytokine measurements as biomarkers to tailor therapeutic strategies for individual patients. In particular, the development of targeted therapies for allergic diseases has underscored the importance of cytokines as biomarkers, with specific cytokines like thymus and activation-regulated chemokine (TARC) being identified as significant in atopic dermatitis [16].

Overall, the intricate interplay of cytokines in rheumatic diseases underscores their dual role as mediators of inflammation and as biomarkers for disease activity. The ongoing research into cytokine signaling pathways and their specific roles in different rheumatic conditions continues to enhance our understanding of these diseases and paves the way for the development of novel therapeutic interventions [1][9].

4.2 Clinical Implications of Cytokine Measurement ​

Cytokines play a pivotal role in the pathophysiology of rheumatic diseases, particularly in conditions such as rheumatoid arthritis (RA). They are protein mediators that significantly influence inflammation, immune responses, cell growth, repair, and fibrosis, all of which are ongoing processes in active RA. The production of various cytokines in the rheumatoid joint contributes to the inflammatory milieu that characterizes this disease, with both pro-inflammatory and anti-inflammatory cytokines being involved in the disease processes[7].

In the context of RA, an imbalance between pro-inflammatory and anti-inflammatory cytokines leads to the induction of autoimmunity and chronic inflammation, ultimately resulting in joint damage. Key pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), and interleukin-6 (IL-6), have been identified as critical mediators in the pathogenesis of RA. Their actions are facilitated through the JAK-STAT signaling pathway, which has emerged as a major therapeutic target in the treatment of inflammatory and autoimmune diseases[[pmid:31520803],[pmid:17525752]].

The measurement of cytokines holds significant clinical implications. Elevated levels of specific cytokines can serve as biomarkers for disease activity, prognosis, and treatment response in patients with rheumatic diseases. For instance, TNF-alpha has been recognized as one of the major signals regulating the production of IL-1 in RA joints, and its levels can be indicative of disease severity[7]. Moreover, the efficacy of various biologic therapies, which target specific cytokines or their receptors, has underscored the importance of cytokine measurement in guiding treatment decisions. The development of JAK inhibitors, which target the signaling pathways of multiple cytokines, represents a significant advancement in the therapeutic landscape for RA and other inflammatory disorders[9].

Furthermore, cytokines have been implicated in the systemic complications associated with rheumatic diseases, such as autoimmune atherosclerosis, which increases cardiovascular risk in patients with RA. The role of cytokines in mediating systemic inflammation highlights the necessity for clinicians to assess cytokine levels not only for local joint inflammation but also for potential systemic effects[17].

In summary, cytokines are central to the pathogenesis of rheumatic diseases and their measurement can provide valuable insights into disease activity, treatment efficacy, and systemic complications. The ongoing research into cytokine networks and their interactions will likely continue to inform clinical strategies and therapeutic interventions in rheumatology.

5 Therapeutic Targeting of Cytokines ​

5.1 Current Cytokine-targeted Therapies ​

Cytokines are small proteins that play a pivotal role in the pathogenesis of rheumatic diseases, including rheumatoid arthritis (RA). They are involved in the regulation of immune responses, inflammation, and tissue homeostasis. In the context of rheumatic diseases, an imbalance between pro-inflammatory and anti-inflammatory cytokines can lead to chronic inflammation, autoimmunity, and subsequent joint damage. The therapeutic targeting of cytokines has emerged as a significant strategy in the management of these conditions.

In rheumatoid arthritis, key cytokines such as tumor necrosis factor (TNF), interleukin (IL)-1, IL-6, IL-17, and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been identified as critical players in disease pathogenesis. TNF and IL-6 are well-established therapeutic targets, with several biologic agents currently available that inhibit their action. The introduction of TNF inhibitors has revolutionized the treatment landscape for RA, providing substantial relief for many patients. However, not all patients respond adequately to these therapies, highlighting the need for additional targets and treatment options[18][19].

Recent research has focused on other cytokines, such as IL-1, which presents a more complex therapeutic target due to discrepancies between animal model results and human clinical outcomes. IL-17 and GM-CSF are being explored as potential new targets, particularly for patients who do not respond to conventional biologics[18].

The development of Janus kinase (JAK) inhibitors represents another significant advancement in cytokine-targeted therapy. These small molecules inhibit intracellular signaling pathways activated by type I and II cytokines, thereby modulating the immune response. JAK inhibitors have shown efficacy in treating RA and other inflammatory diseases, although they also carry risks of adverse effects such as infections and hyperlipidemia[2][20].

The current landscape of cytokine-targeted therapies in rheumatic diseases is characterized by a growing arsenal of biologics and small molecules aimed at modulating the immune response. Despite the progress made, challenges remain, including treatment failures, safety concerns, and the need for personalized approaches to therapy. Continuous research is necessary to further elucidate the roles of various cytokines and to identify the most effective therapeutic strategies for managing rheumatic diseases[19][20].

In summary, cytokines are central to the pathogenesis of rheumatic diseases and represent crucial therapeutic targets. The success of existing therapies targeting TNF and IL-6, along with the advent of JAK inhibitors, underscores the importance of cytokine modulation in improving patient outcomes. However, ongoing efforts to identify additional cytokine targets and refine therapeutic strategies are essential for addressing the complexities of these diseases and enhancing treatment efficacy[18][19][20].

5.2 Future Directions in Cytokine Modulation ​

Cytokines play a pivotal role in the pathogenesis of rheumatic diseases, particularly rheumatoid arthritis (RA). They are small proteins that mediate and regulate immunity, inflammation, and hematopoiesis. In the context of RA, cytokines are crucial in the induction and maintenance of inflammation, contributing to joint destruction and chronic inflammatory processes. Key cytokines involved in RA include tumor necrosis factor (TNF), interleukin (IL)-6, IL-1, IL-17, and granulocyte-macrophage colony-stimulating factor (GM-CSF) [18].

The therapeutic targeting of cytokines has emerged as a significant advancement in the management of rheumatic diseases. The blockade of TNF has proven effective in clinical practice, demonstrating the potential of cytokines as therapeutic targets. However, partial and non-responses to TNF inhibitors have highlighted the need for identifying additional cytokine targets. Current research is focusing on other cytokines such as IL-6, IL-15, IL-17, and IL-32, which have shown promising data in clinical trials [21]. The introduction of biologic agents that target these cytokines has revolutionized treatment strategies, allowing for improved management of inflammation and symptoms associated with RA [19].

Future directions in cytokine modulation involve exploring intracellular signaling pathways associated with cytokine activity. The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways are critical in mediating the effects of type I and II cytokines. JAK inhibitors have emerged as effective therapeutic agents for RA, although they are associated with certain adverse effects such as increased risk of infections and hyperlipidemia [20]. The ongoing development of selective JAK inhibitors and potential strategies targeting STATs present new avenues for treatment [20].

Furthermore, understanding the complex interactions between cytokines and their regulatory networks remains essential for developing more effective therapeutic strategies. Research continues to elucidate the roles of various cytokines in RA, aiming to identify optimal therapeutic targets that can enhance treatment efficacy and minimize side effects [1]. As our understanding of cytokine biology evolves, the potential for innovative cytokine-based therapies in rheumatic diseases is promising, indicating a future where more tailored and effective treatment options may be available [22].

6 Conclusion ​

Cytokines are integral to the pathogenesis of rheumatic diseases, particularly rheumatoid arthritis (RA), where they orchestrate inflammation and immune responses. The key findings of this review highlight the crucial roles of both pro-inflammatory and anti-inflammatory cytokines in mediating disease processes. Pro-inflammatory cytokines, such as TNF-α and IL-6, are central to the induction of chronic inflammation and joint destruction, while anti-inflammatory cytokines play a regulatory role in mitigating these effects. Current therapeutic strategies targeting cytokines, particularly biologics and JAK inhibitors, have significantly advanced the management of rheumatic diseases, though challenges remain in terms of treatment efficacy and safety. Future research should focus on elucidating the complex cytokine networks and exploring novel therapeutic targets to enhance patient outcomes. The ongoing investigation into cytokine biology holds promise for the development of more personalized and effective treatment approaches in rheumatology.

References ​

  • [1] Iain B McInnes;Georg Schett. Cytokines in the pathogenesis of rheumatoid arthritis.. Nature reviews. Immunology(IF=60.9). 2007. PMID:17525752. DOI: 10.1038/nri2094.
  • [2] Christine Liu;Jacqueline Kieltyka;Roy Fleischmann;Massimo Gadina;John J O'Shea. A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?. Arthritis & rheumatology (Hoboken, N.J.)(IF=10.9). 2021. PMID:34180156. DOI: 10.1002/art.41906.
  • [3] Z Szekanecz;A E Koch;S L Kunkel;R M Strieter. Cytokines in rheumatoid arthritis. Potential targets for pharmacological intervention.. Drugs & aging(IF=3.8). 1998. PMID:9606615. DOI: 10.2165/00002512-199812050-00004.
  • [4] P J Moulton. Inflammatory joint disease: the role of cytokines, cyclooxygenases and reactive oxygen species.. British journal of biomedical science(IF=4.6). 1996. PMID:9069110. DOI: .
  • [5] Attila Mócsai;László Kovács;Péter Gergely. What is the future of targeted therapy in rheumatology: biologics or small molecules?. BMC medicine(IF=8.3). 2014. PMID:24620738. DOI: 10.1186/1741-7015-12-43.
  • [6] Prashant Chauhan;Arathi Nair;Ashok Patidar;Jagneshwar Dandapat;Arup Sarkar;Bhaskar Saha. A primer on cytokines.. Cytokine(IF=3.7). 2021. PMID:33581983. DOI: 10.1016/j.cyto.2021.155458.
  • [7] M Feldmann;F M Brennan;D Chantry;C Haworth;M Turner;E Abney;G Buchan;K Barrett;D Barkley;A Chu. Cytokine production in the rheumatoid joint: implications for treatment.. Annals of the rheumatic diseases(IF=20.6). 1990. PMID:2197999. DOI: .
  • [8] T Thalhamer;M A McGrath;M M Harnett. MAPKs and their relevance to arthritis and inflammation.. Rheumatology (Oxford, England)(IF=4.4). 2008. PMID:18187523. DOI: 10.1093/rheumatology/kem297.
  • [9] Yvan Jamilloux;Thomas El Jammal;Lucine Vuitton;Mathieu Gerfaud-Valentin;Sébastien Kerever;Pascal Sève. JAK inhibitors for the treatment of autoimmune and inflammatory diseases.. Autoimmunity reviews(IF=8.3). 2019. PMID:31520803. DOI: 10.1016/j.autrev.2019.102390.
  • [10] M Feldmann;F M Brennan;D Chantry;C Haworth;M Turner;P Katsikis;M Londei;E Abney;G Buchan;K Barrett. Cytokine assays: role in evaluation of the pathogenesis of autoimmunity.. Immunological reviews(IF=8.3). 1991. PMID:2045116. DOI: 10.1111/j.1600-065x.1991.tb00580.x.
  • [11] Iain B McInnes;Christopher D Buckley;John D Isaacs. Cytokines in rheumatoid arthritis - shaping the immunological landscape.. Nature reviews. Rheumatology(IF=32.7). 2016. PMID:26656659. DOI: 10.1038/nrrheum.2015.171.
  • [12] Edit Bodolay;Alisa E Koch;Joon Kim;Gyula Szegedi;Zoltan Szekanecz. Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases.. Journal of cellular and molecular medicine(IF=4.2). 2002. PMID:12417052. DOI: 10.1111/j.1582-4934.2002.tb00514.x.
  • [13] Naoki Kondo;Takeshi Kuroda;Daisuke Kobayashi. Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis.. International journal of molecular sciences(IF=4.9). 2021. PMID:34681582. DOI: 10.3390/ijms222010922.
  • [14] Marc Feldmann. Development of anti-TNF therapy for rheumatoid arthritis.. Nature reviews. Immunology(IF=60.9). 2002. PMID:12033742. DOI: 10.1038/nri802.
  • [15] Liv T Osnes;Britt Nakken;Edit Bodolay;Peter Szodoray. Assessment of intracellular cytokines and regulatory cells in patients with autoimmune diseases and primary immunodeficiencies - novel tool for diagnostics and patient follow-up.. Autoimmunity reviews(IF=8.3). 2013. PMID:23541481. DOI: .
  • [16] Susanne Radonjic-Hoesli;Nikolay Pavlov;Hans-Uwe Simon;Dagmar Simon. Are blood cytokines reliable biomarkers of allergic disease diagnosis and treatment responses?. The Journal of allergy and clinical immunology(IF=11.2). 2022. PMID:35934679. DOI: 10.1016/j.jaci.2022.06.008.
  • [17] Zoltán Szekanecz;György Kerekes;Edit Végh;Zsófia Kardos;Zsuzsa Baráth;László Tamási;Yehuda Shoenfeld. Autoimmune atherosclerosis in 3D: How it develops, how to diagnose and what to do.. Autoimmunity reviews(IF=8.3). 2016. PMID:26979271. DOI: .
  • [18] Mélissa Noack;Pierre Miossec. Selected cytokine pathways in rheumatoid arthritis.. Seminars in immunopathology(IF=9.2). 2017. PMID:28213794. DOI: 10.1007/s00281-017-0619-z.
  • [19] Stefan Siebert;Alexander Tsoukas;Jamie Robertson;Iain McInnes. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases.. Pharmacological reviews(IF=17.3). 2015. PMID:25697599. DOI: 10.1124/pr.114.009639.
  • [20] Daniella M Schwartz;Michael Bonelli;Massimo Gadina;John J O'Shea. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.. Nature reviews. Rheumatology(IF=32.7). 2016. PMID:26633291. DOI: 10.1038/nrrheum.2015.167.
  • [21] Darren L Asquith;Iain B McInnes. Emerging cytokine targets in rheumatoid arthritis.. Current opinion in rheumatology(IF=4.3). 2007. PMID:17414950. DOI: 10.1097/BOR.0b013e3280eec78c.
  • [22] Tsutomu Takeuchi. Cytokines and cytokine receptors as targets of immune-mediated inflammatory diseases-RA as a role model.. Inflammation and regeneration(IF=6.6). 2022. PMID:36451227. DOI: 10.1186/s41232-022-00221-x.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

cytokines · rheumatic diseases · inflammation · autoimmunity · therapeutic targets

© 2025 MaltSci